Key Points
- CEO Benjamin Palleiko sold 10,940 shares on Nov. 24 at an average price of $13.45 for $147,143, trimming his stake by 2.56% to 416,189 shares (≈$5.6M).
- KalVista's most recent quarter beat expectations with EPS of ($0.92) vs. consensus ($0.96) and revenue of $13.69M versus estimates of $6.03M, showing a notable revenue surprise.
- Wall Street sentiment is largely positive—10 analysts rate the stock a Buy and one a Sell, with an average target price of $26.63 and several firms setting $28 targets.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CFO Brian Piekos sold 4,471 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the sale, the chief financial officer owned 10,529 shares in the company, valued at approximately $141,615.05. This represents a 29.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
KalVista Pharmaceuticals Stock Performance
NASDAQ KALV traded up $0.82 on Thursday, hitting $14.10. The stock had a trading volume of 1,928,887 shares, compared to its average volume of 933,997. The firm has a 50-day moving average of $12.04 and a 200-day moving average of $12.87. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $17.28. The company has a market capitalization of $712.70 million, a price-to-earnings ratio of -3.58 and a beta of -0.04.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analysts' expectations of $6.03 million. As a group, research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on KALV shares. Citigroup reiterated a "market outperform" rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. JMP Securities boosted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a "market outperform" rating in a research report on Friday, September 12th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. Citizens Jmp reduced their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating for the company in a research report on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $26.63.
View Our Latest Analysis on KalVista Pharmaceuticals
Institutional Investors Weigh In On KalVista Pharmaceuticals
Institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its holdings in KalVista Pharmaceuticals by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company's stock valued at $165,000 after buying an additional 818 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock worth $46,000 after acquiring an additional 1,292 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company's stock worth $615,000 after purchasing an additional 1,458 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in KalVista Pharmaceuticals by 26.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company's stock worth $110,000 after purchasing an additional 2,061 shares during the last quarter. Finally, Corebridge Financial Inc. grew its stake in shares of KalVista Pharmaceuticals by 12.7% during the first quarter. Corebridge Financial Inc. now owns 19,094 shares of the specialty pharmaceutical company's stock valued at $220,000 after buying an additional 2,149 shares during the last quarter.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
